M. Gardizi

发表

A Genomics-Based Classification of Human Lung Tumors

G. Getz, S. Carter, D. Hayes, 2013, Science Translational Medicine.

Cell-autonomous and non-cell-autonomous mechanisms of transformation by amplified FGFR1 in lung cancer.

Roman K. Thomas, T. Zander, M. Peifer, 2014, Cancer discovery.

Sorafenib and everolimus in patients with advanced solid tumors and KRAS‐mutated NSCLC: A phase I trial with early pharmacodynamic FDG‐PET assessment

J. Franklin, U. Fuhr, J. Wolf, 2020, Cancer medicine.

Targeting FGFR1-amplified lung squamous cell carcinoma with the selective pan-FGFR inhibitor BGJ398.

M. Hidalgo, L. Sequist, F. Ringeisen, 2014 .

the International Association for the Study of Lung Cancer Implementation of Amplicon Parallel Sequencing Leads to Improvement of Diagnosis and Therapy of Lung Cancer Patients

T. Zander, M. Odenthal, Y. Ko, 2015 .

A decreased ratio between serum levels of the antagonistic angiopoietins 1 and 2 indicates tumour progression of malignant melanoma

T. Krieg, C. Kurschat, P. Kurschat, 2012, Archives of Dermatological Research.

Rationale for co-targeting IGF-1R and ALK in ALK fusion positive lung cancer

William Pao, Zhongming Zhao, Ronglai Shen, 2014, Nature Medicine.

PIK3CA mutations in non-small cell lung cancer (NSCLC): Genetic heterogeneity, prognostic impact and incidence of prior malignancies

M. Hellmich, T. Zander, Y. Ko, 2014, Oncotarget.

Implementation of Amplicon Parallel Sequencing Leads to Improvement of Diagnosis and Therapy of Lung Cancer Patients

T. Zander, M. Odenthal, Y. Ko, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Ampli fi cation Status in Therapy-Naïve Adeno-and Squamous Cell Carcinomas of the Lung

T. Zander, Y. Ko, K. Hekmat, 2015 .

MET Amplification Status in Therapy-Naïve Adeno- and Squamous Cell Carcinomas of the Lung

T. Zander, Y. Ko, K. Hekmat, 2014, Clinical Cancer Research.

Activated RET and ROS: two new driver mutations in lung adenocarcinoma.

J. Wolf, R. Buettner, H. Schildhaus, 2013, Translational lung cancer research.

Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial.

M. Hellmich, J. Franklin, E. Smit, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Spatial Tumor Heterogeneity in Lung Cancer with Acquired Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Resistance: Targeting High-Level MET-Amplification and EGFR T790M Mutation Occurring at Different Sites in the Same Patient.

Roman K. Thomas, F. Leenders, J. Wolf, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Complete metabolic response in a patient with repeatedly relapsed non-small cell lung cancer harboring ROS1 gene rearrangement after treatment with crizotinib.

D. Maintz, T. Zander, J. Wolf, 2013, Lung cancer.

BARIS: A phase I trial to evaluate the safety and tolerability of combined BIBF 1120 and RAD001 in solid tumors and to determine the maximum tolerated dose (MTD) of the combination.

T. Zander, M. Sos, J. Wolf, 2012 .

Implementation of Amplicon Parallel Sequencing Leads to Improvement of Diagnosis and Therapy of Lung Cancer Patients

T. Zander, M. Odenthal, Y. Ko, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

MET Amplification Status in Therapy-Naïve Adeno- and Squamous Cell Carcinomas of the Lung

T. Zander, Y. Ko, K. Hekmat, 2014, Clinical Cancer Research.

MA07.05 EUCROSS: A European Phase II Trial of Crizotinib in Advanced Adenocarcinoma of the Lung Harboring ROS1 Rearrangements - Preliminary Results

M. Hellmich, J. Franklin, E. Felip, 2017 .